Recommended Topic Related To:

Aubagio

"Oct. 31, 2012 -- Two new trials offer proof that a leukemia drug long used to treat multiple sclerosis works better than a common treatment.

When compared with the widely used drug interferon beta, the leukemia drug alemtuzumab reduce"...

Aubagio

INDICATIONS

AUBAGIO® is indicated for the treatment of patients with relapsing forms of multiple sclerosis [see Clinical Studies].

DOSAGE AND ADMINISTRATION

The recommended dose of AUBAGIO is 7 mg or 14 mg orally once daily. AUBAGIO can be taken with or without food.

Monitoring to assess safety
  • Obtain transaminase and bilirubin levels within 6 months before initiation of AUBAGIO therapy. Monitor ALT levels at least monthly for six months after starting AUBAGIO [see WARNINGS AND PRECAUTIONS].
  • Obtain a complete blood cell count (CBC) within 6 months before the initiation of treatment with AUBAGIO. Further monitoring should be based on signs and symptoms of infection [see WARNINGS AND PRECAUTIONS].
  • Prior to initiating AUBAGIO, screen patients for latent tuberculosis infection with a tuberculin skin test [see WARNINGS AND PRECAUTIONS].
  • Check blood pressure before start of AUBAGIO treatment and periodically thereafter [see WARNINGS AND PRECAUTIONS].

HOW SUPPLIED

Dosage Forms And Strengths

AUBAGIO is available as 7 mg and 14 mg tablets.

The 14 mg tablet is a pale blue to pastel blue, pentagonal film-coated tablet with the dose strength, “14” imprinted on one side and engraved with the corporate logo on the other side. Each tablet contains 14 mg of teriflunomide.

The 7 mg tablet is a very light greenish-bluish grey to pale greenish-blue, hexagonal film-coated tablet with dose strength “7” imprinted on one side and engraved with the corporate logo on other side. Each tablet contains 7 mg of teriflunomide.

Storage And Handling

AUBAGIO is available 7 mg and 14 mg tablets.

The 14 mg tablet is pale blue to pastel blue, pentagonal film-coated tablets with imprint on one side dose strength given as number 14 and engraved with corporate logo on the other side.

The 7 mg tablet is very light greenish-bluish grey to pale greenish-blue, hexagonal film-coated tablets with dose strength “7” imprinted on one side and engraved with corporate logo on other side. Each tablet contains 7 mg of teriflunomide.

AUBAGIO 14 mg tablets are supplied as:

NDC 58468-0210-2 Carton of 28 tablets containing 1 wallet composed of 2 folded blister cards of 14 tablets per blister card

NDC 58468-0210-1 Carton of 5 tablets with one blister card with five tablets AUBAGIO 7 mg tablets are supplied as:

NDC 58468-0211-1 Carton of 28 tablets containing 1 wallet composed of 2 folded blister cards of 14 tablets per blister card

NDC 58468-0211-2 Carton of 5 tablets with one blister card with five tablets

Store at 68°F to 77°F (20°C to 25°C) with excursions permitted between 59°F and 86°F (15°C and 30°C).

Genzyme Corporation, 500 Kendall Street, Cambridge, MA 02142, A Sanofi Company. September 2012

Last reviewed on RxList: 9/21/2012
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Multiple Sclerosis

Get the latest treatment options.

advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations